1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: Polar functionality and its effect on anti-HIV-1 activity

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 20, 2002, Pages 2997-3000

  Hale, Jeffrey J ^a   Budhu, Richard J ^a   Mills, Sander G ^a   MacCoss, Malcolm ^a   Gould, Sandra L ^a   DeMartino, Julie A ^a   Springer, Martin S ^a   Siciliano, Salvatore J ^a   Malkowitz, Lorraine ^a   Schleif, William A ^a   Hazuda, Daria ^a   Miller, Michael ^a   Kessler, Joseph ^a   Danzeisen, Renee ^a   Holmes, Karen ^a   Lineberger, Janet ^a   Carella, Anthony ^a   Carver, Gwen ^a   Emini, Emilio A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CALCIUM CHANNEL L TYPE; CHEMOKINE RECEPTOR CCR5; PYRROLIDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; COMBINATORIAL CHEMISTRY; DRUG EFFECT; DRUG STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; CALCIUM CHANNELS, L-TYPE; CHEMISTRY, PHYSICAL; CHO CELLS; CRICETINAE; HALF-LIFE; HELA CELLS; HIV-1; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; RATS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 18644374488     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00605-4     Document Type: Article

References (11)

1. Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A., Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A. Nature. 381:1996;667.
2. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., Landau N.R. Nature. 381:1996;661.
3. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., Fujino M. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5698.
4. Tagat J.R., Steensma R.W., McCombie S.W., Narareno D.V., Lin S.-I., Neustadt B.R., Cox K., Xu S., Wojcik L., Murray M.G., Vantuno N., Baroudy B.M., Strizki J.M. J. Med. Chem. 44:2001;3343. and references therein.
5. Finke P.E., Oates B., Mills S.G., MacCoss M., Malkowitz L., Springer M.S., Gould S.L., DeMartino J.A., Carella A., Carver G., Holmes K., Danzeisen R., Hazuda D., Kessler J., Lineberger J., Miller M., Schlief W.A., Emini E.A. Bioorg. Med. Chem. Lett. 11:2001;2475. and references therein.
6. Hale J.J., Budhu R.J., Holson E.B., Finke P.E., Oates B., Mills S.G., MacCoss M., Gould S.L., DeMartino J.A., Springer M.S., Siciliano S., Malkowitz L., Schlief W.A., Hazuda D., Miller M., Kessler J., Danzeisen R., Holmes K., Lineberger J., Carella A., Carver G., Emini E.A. Bioorg. Med. Chem. Lett. 11:2001;2741.
7. Willoughby C.W., Berk S.C., Rosauer K.G., Delgrado S., Chapman K.T., Gould S.L., Springer M.S., Malkowitz L., Schlief W.A., Hazuda D., Miller M., Kessler J., Danzeisen R., Holmes K., Lineberger J., Carella A., Carver G., Emini E.A. Bioorg. Med. Chem. Lett. 11:2001;3137.
8. Hale J.J., Budhu R.J., Mills S.G., MacCoss M., Malkowitz L., Gould S.L., Springer M.S. Bioorg. Med. Chem. Lett. 11:2001;1437.
9. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M.D. Science. 287:2000;646.
10. The discordant abilities of CCR5 monoclonal antibodies to block ligand binding to the CCR5 receptor and to inhibit HIV-1 infection has been rationalized to arise from the potential existence of multiple conformational states of CCR5. See, Lee, B.; Sharron, M.; Blanpain, C.; Doranz, B. J.; Vakili, J.; Setoh, P.; Berg, E.; Liu, G.; Durell, S. R.; Parmentier, M.; Chang, C. N.; Price, K.; Tsang, M.; Doms, R. W. J. Biol. Chem. 1999, 274, 9617.
11. 50=590 nM. For assay protocol: Reynolds, I. J.; Snowman, A. M.; Snyder, S. H. J. Pharm. Exp. Therap. 1986, 237, 731.